TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02916524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic Feature Analysis (SFA)
Description: SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Description: SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
Study: NCT03768986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard referral for HIV testing
Description: Participants receive standard referral for HIV testing in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard referral for HIV testing
Description: Participants receive standard referral for HIV testing in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online risk reduction training
Description: Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online risk reduction training
Description: Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
Study: NCT01822093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytovir-ADV
Description: A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results \> 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group
Study: NCT03768986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement
Description: Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
Study: NCT02630927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-519
Description: AG519 will be tested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-519
Description: AG519 will be tested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AG-519
Description: AG519 will be tested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AG-519
Description: AG519 will be tested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-519
Description: AG519 will be tested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be tested.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be tested.
Study: NCT00191984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
Study: NCT01654289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
Study: NCT02274350

Intervention type: RADIATION
Intervention: radiation therapy
Description: Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
Study: NCT02388399

Intervention type: PROCEDURE
Intervention: Device
Description: Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)

Intervention type: PROCEDURE
Intervention: Device
Description: Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
Study: NCT04118088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Description: Darvadstrocel suspension of human expanded adipose stem cells.
Study: NCT01403805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)
Description: Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (Flubik HA, 16100EZZ01207000)
Description: Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
Study: NCT03271190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE SPANISH/MUSIC
Description: Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ENGAGE DISCOVERY
Description: Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
Study: NCT01403805

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination (Flubik HA, 16100EZZ01207000)
Description: Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific frequency of oral care
Description: 1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
Study: NCT01699802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaled anaesthetic agent
Study: NCT02243488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irise Easy Pad & Menstrual Health Education
Description: Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
Study: NCT04554901

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa
Description: 2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
Study: NCT03271528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
Study: NCT00621686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT03943342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01592799

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Throat swab and/or nasopharyngeal swab
Description: Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Log Sheet will be used to collected data on a monthly basis for the following age groups: \< 6 months; 6-23 months; 24-59 months; \> 5 years.
Study: NCT02081261

Intervention type: PROCEDURE
Intervention: Coronary artery bypass surgery
Description: coronary artery bypass surgery
Study: NCT02058628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin + BPO
Description: Gel containing 1.2% clindamycin and 3% BPO for once daily application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: Cream containing 20% azelaic acid for twice daily application
Study: NCT01790620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CVVHD
Description: CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
Study: NCT01218087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial cup device and Moldable positioner
Description: The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moldable positioner device
Description: This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moldable positioner device
Description: This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
Study: NCT02604992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Dronabinol oral solution, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Dronabinol oral capsule, under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Dronabinol oral capsule, under fasted conditions
Study: NCT04714879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: anodal tDCS
Description: anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Device: no stimulation
Description: sham stimulation
Study: NCT03285516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Aid Reduction Treatment
Description: START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
Study: NCT01139125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Cystagon) Cysteamine Bitartrate
Description: Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT02547428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN SR
Description: CTN SR tablets, daily, Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN SR
Description: CTN SR tablets, daily, Orally.
Study: NCT06182631

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A band will be placed on the arm before IV insertion for placebo effect.
Study: NCT04302727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Med-South Weight Loss Intervention
Description: Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WW
Description: If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
Study: NCT02547428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching-placebo tablets daily, orally.
Study: NCT02356939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraductal removable stent custom-made segment (2 cm)
Description: : In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent extraction by ERCP
Description: stent extraction by endoscopic retrograde cholangio-pancreatography
Study: NCT01663961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 OCAS
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral
Study: NCT02250911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: webcasts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessments

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessments
Study: NCT00806897

Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
Study: NCT03526250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT02250911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT01695993

Intervention type: DEVICE
Group type: OTHER
Intervention: Acupressure bands
Description: Bilateral acupressure wrist bands

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure bands
Description: Bilateral acupressure wrist bands
Study: NCT04335851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video based aerobic exercise
Description: During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes.
Study: NCT01695993

Intervention type: OTHER
Group type: OTHER
Intervention: Expectancy-neutral handout
Description: The expectancy neutral handout has neutral information regarding the acupressure bands
Study: NCT01760031

Intervention type: OTHER
Intervention: Ischemic preconditioning
Description: Subjects received ischemic preconditioning previous to cardiac catheterization
Study: NCT03153904

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
Study: NCT01695993

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Expectancy-neutral MP3
Description: Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.